Sponsor content
1 result(s) found, displaying 1 to 1
-
Australian public assessment report (AusPar)New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.
Kadmon Oceania Pty Ltd
Regulatory activities for this sponsor.